Psoriasis medical therapy: Difference between revisions
| Line 35: | Line 35: | ||
Some topical agents are used in conjunction with other therapies, especially phototherapy. | Some topical agents are used in conjunction with other therapies, especially phototherapy. | ||
====Chronic Pharmacotherapies==== | |||
'''Systemic treatment''' | |||
Psoriasis which is resistant to [[topical|topical treatment]] and [[light therapy|phototherapy]] is treated by [[medication]]s that are taken internally by pill or [[Injection (medicine)|injection]]. This is called systemic treatment. Patients undergoing systemic treatment are required to have regular [[Blood test|blood]] and [[liver function tests]] because of the [[toxicity]] of the [[medication]]. [[Pregnancy]] must be avoided for the majority of these treatments. Most people experience a recurrence of psoriasis after systemic treatment is discontinued. | |||
The three main traditional systemic treatments are the [[immunosuppressive drug|immunosupressant]] drugs [[methotrexate]] and [[cyclosporine]], and retinoids, which are synthetic forms of [[vitamin A]]. Other additional drugs, not specifically licensed for psoriasis, have been found to be effective. These include the [[antimetabolite]] [[tioguanine]], the [[cytotoxic]] agent [[hydroxyurea]], [[sulfasalazine]], the [[immunosuppressive drug|immunosupressants]] [[mycophenolate mofetil]], [[azathioprine]] and oral [[tacrolimus]]. These have all been used effectively to treat psoriasis when other treatments have failed. Although not licensed in many other countries [[fumaric acid|fumaric acid esters]] have also been used to treat severe psoriasis in Germany for over 20 years. | |||
[[Biologics]] are manufactured proteins that interrupt the immune process involved in psoriasis. Unlike generalised [[immunosuppressive drug|immunosuppressant]] therapies such as methotrexate, biologics focus on specific aspects of the immune function leading to psoriasis. These drugs (interleukin antagonists) are relatively new, and their long-term impact on immune function is unknown. They are very expensive and only suitable for very few patients with psoriasis. Ustekinumab ([[IL-12]] and IL-23 blocker) shows hopeful results for psoriasis therapy. | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
Revision as of 16:13, 22 August 2012
|
Psoriasis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Psoriasis medical therapy On the Web |
|
American Roentgen Ray Society Images of Psoriasis medical therapy |
|
Risk calculators and risk factors for Psoriasis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Medical Therapy
There can be substantial variation between individuals in the effectiveness of specific psoriasis treatments. Because of this, dermatologists often use a trial-and-error approach to finding the most appropriate treatment for their patient. The decision to employ a particular treatment is based on the type of psoriasis, its location, extent and severity. The patient’s age, sex, quality of life, comorbidities, and attitude toward risks associated with the treatment are also taken into consideration.
In 2008, the FDA approved three new treatment options[1] available to psoriasis patients:
- Taclonex Scalp, a new topical ointment for treating scalp psoriasis;
- The Xtrac Velocity excimer laser system, which emits a high-intensity beam of ultraviolet light, can treat moderate to severe psoriasis
- The biologic drug adalimumab (brand name Humira) was also approved to treat moderate to severe psoriasis. Adalimumab had already been approved to treat psoriatic arthritis.
Medications with the least potential for adverse reactions are preferentially employed. If the treatment goal is not achieved then therapies with greater potential toxicity may be used. Medications with significant toxicity are reserved for severe unresponsive psoriasis. This is called the psoriasis treatment ladder.[2] As a first step, medicated ointments or creams, called topical treatments, are applied to the skin. If topical treatment fails to achieve the desired goal then the next step would be to expose the skin to ultraviolet (UV) radiation. This type of treatment is called phototherapy. The third step involves the use of medications which are taken internally by pill or injection. This approach is called systemic treatment.
Over time, psoriasis can become resistant to a specific therapy. Treatments may be periodically changed to prevent resistance developing (tachyphylaxis) and to reduce the chance of adverse reactions occurring. This is called treatment rotation.
Antibiotics are generally not indicated in routine treatment of psoriasis. However, antibiotics may be employed when an infection, such as that caused by the bacteria Streptococcus, triggers an outbreak of psoriasis, as in certain cases of guttate psoriasis.
A psychological symptom management programme has been reported as being a helpful adjunct to traditional therapies in the management of psoriasis.[3]
Pharmacotherapy
Acute Pharmacotherapies
Topical treatment
Bath solutions and moisturizers help sooth affected skin and reduce the dryness which accompanies the build-up of skin on psoriatic plaques. Medicated creams and ointments applied directly to psoriatic plaques can help reduce inflammation, remove built-up scale, reduce skin turn over, and clear affected skin of plaques. Ointment and creams containing coal tar (no longer available on prescription in the UK), dithranol (anthralin), corticosteroids, vitamin D3 analogues (for example, calcipotriol), and retinoids are routinely used. The mechanism of action of each is probably different but they all help to normalise skin cell production and reduce inflammation. Activated vitamin D and its analogues are highly effective inhibitors of skin cell proliferation.
The disadvantages of topical agents are variably that they can often irritate normal skin, can be time consuming and awkward to apply, cannot be used for long periods, can stain clothing or have a strong odour. As a result, it is sometimes difficult for people to maintain the regular application of these medications. Abrupt withdrawal of some topical agents, particularly corticosteroids, can cause an aggressive recurrence of the condition. This is known as a rebound of the condition.
Some topical agents are used in conjunction with other therapies, especially phototherapy.
Chronic Pharmacotherapies
Systemic treatment
Psoriasis which is resistant to topical treatment and phototherapy is treated by medications that are taken internally by pill or injection. This is called systemic treatment. Patients undergoing systemic treatment are required to have regular blood and liver function tests because of the toxicity of the medication. Pregnancy must be avoided for the majority of these treatments. Most people experience a recurrence of psoriasis after systemic treatment is discontinued.
The three main traditional systemic treatments are the immunosupressant drugs methotrexate and cyclosporine, and retinoids, which are synthetic forms of vitamin A. Other additional drugs, not specifically licensed for psoriasis, have been found to be effective. These include the antimetabolite tioguanine, the cytotoxic agent hydroxyurea, sulfasalazine, the immunosupressants mycophenolate mofetil, azathioprine and oral tacrolimus. These have all been used effectively to treat psoriasis when other treatments have failed. Although not licensed in many other countries fumaric acid esters have also been used to treat severe psoriasis in Germany for over 20 years.
Biologics are manufactured proteins that interrupt the immune process involved in psoriasis. Unlike generalised immunosuppressant therapies such as methotrexate, biologics focus on specific aspects of the immune function leading to psoriasis. These drugs (interleukin antagonists) are relatively new, and their long-term impact on immune function is unknown. They are very expensive and only suitable for very few patients with psoriasis. Ustekinumab (IL-12 and IL-23 blocker) shows hopeful results for psoriasis therapy.
References
- ↑ "Psoriasis Medical Breakthroughs" Parade.com
- ↑ Lofholm PW (2000). "The psoriasis treatment ladder: a clinical overview for pharmacists". US Pharm. 25 (5): 26–47.
- ↑ "Research Findings Register: summary number 637". Retrieved 2007-07-22.